Our findings demonstrate that pyrotinib-based regimens are both effective and safe for HER2-positive advanced breast cancer patients with liver metastases, with anemia and liver injury being the primary adverse effects, which were generally manageable and clinically tolerable. The gene discussed is ERBB2; the disease is anemia.